Antitumour compositions containing taxane derivatives

• US 5,728,687 A
• Filed: 05/09/1995
• Issued: 03/17/1998
• Est. Priority Date: 11/10/1992
• Status: Expired due to Term

• Current Assignee: Aventis Pharma SA (Sanofi ), Societe Des Procedes Et Machines Speciales
• Original Assignee: Rhone-Poulenc Rorer S.A. (Sanofi )
• Inventors: Bissery, Marie-Christine
• Primary Examiner(s): KRASS, FREDERICK F
• Application Number:
  US08/424,470
• Time in Patent Office: 1,043 Days
• Field of Search: 514/183, 514/90, 514/151, 514/245, 514/256, 514/274, 514/275, 514/449
• US Class Current: 514/90
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/7072 having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 38/20 Interleukins [IL]
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/50 acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07D 305/14 condensed with carbocyclic rings or ring systems
• CPC Class Codes: C12Y 305/01001 : Asparaginase (3.5.1.1)

Abstract

Pharmaceutical compositions having therapeutic synergy comprising taxol or Taxotere or analogues thereof combined with at least one therapeutically useful substance for treating neoplastic diseases.

Claims

1. A pharmaceutical composition having therapeutic synergy comprising at least one taxane selected from the group consisting of taxol, Taxotere and derivatives thereof in combination with an effective amount of at least one of an alkylating agent, epidophyllotoxin, antimetabolite, or vinca alkaloid.

2. A pharmaceutical composition according to claim 1, wherein the alkylating agent is cyclophosphamide, ifosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine.

3. A pharmaceutical composition according to claim 1, wherein the antimetabolite is 5-fluorouracil, cytarabine or a folic acid analog.

4. A pharmaceutical composition according to claim 1, wherein the vinca alkaloid is vinblastine, vincristine, or their synthetic analogues.

5. A pharmaceutical composition according to claim 1, wherein the epidophyllotoxin is etoposide or teniposide.

6. A pharmaceutical composition according to claim 1, wherein the composition contains from 10 to 90% by weight of at least one taxane.

7. A pharmaceutical composition according to claim 1, wherein said composition is useful in the treatment of neoplastic diseases.

9. A pharmaceutical composition according to claim 3, wherein said folic analog is methotrexate, idatrexate or trimetrexate.

8. A pharmaceutical composition having therapeutic synergy comprising at least one taxane selected from the group consisting of taxol, Taxotere and derivatives thereof in combination with a synergistically effective amount of at least one of cyclophosphamide, etoposide, 5-fluorouracil or vincristine.